Compare Dicks Sporting Goods Inc (DKS) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dicks Sporting Goods Inc vs Sanofi SA — how do they compare? Dicks Sporting Goods Inc trades at $135.72 (market cap $13.26B), while Sanofi SA trades at $40.14 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 7.2× Dicks Sporting Goods Inc's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Dicks Sporting Goods Inc for 19 Days and Sanofi SA for 94 Days on average.
| DKS | SNY | |
|---|---|---|
Market Cap | $13.26B | $95.18B |
Volume | 2,292,035 | 2,995,646 |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $52.34 |
52-Week Low | $121.15 | $39.51 |
Typical Hold Time | 19 Days | 94 Days |
Enterprise Value | $20.31B | $114.48B |
Dividend Yield | 3.71% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DICK'S Sporting Goods (DKS) trades at $134.91, up 2.84% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains solid fundamentals with a P/E of 14.86 and ROE of 18.47%, though recent earnings showed a Q2 2026 miss. Analyst consensus remains strongly positive with 56.9% buy ratings and a $153.30 price target, representing 13.6% upside potential from current levels.
While facing securities litigation headwinds, DKS demonstrates operational strength with $1.31B operating cash flow and consistent dividend payments. The stock offers value with attractive valuation metrics, but investors should monitor the ongoing class action lawsuits and potential impact on near-term sentiment despite the fundamentally sound business model.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
